The CEO of Clerkenwell Health, a British mental health start-up, explains how psychedelic-assisted therapy might hold the key to patient-centric treatment.

Psychedelic medicines are at a turning point. Used in combination with structured talking therapies, these compounds are being trialled in the treatment of mental health conditions. Last year, for instance, UK regulators gave the green light for the first clinical trial of the use of the psychedelic drug dimethyltryptamine (DMT) to treat depression.